Connect with us


Novavax confident Covid vaccine will receive FDA authorization in June after delays



Novavax is confident its Covid-19 vaccine will receive the endorsement of the Food and Drug Administration’s advisory committee early this summer, executives said this week.

The FDA committee is scheduled to meet on June 7 to review Novavax’s submission. An endorsement from the committee, which is made up of independent experts, would mean the drug regulator is almost certain to quickly authorize the two-dose vaccine for use in the U.S.

CEO Stanley Erck said this week that Novavax’s manufacturing partner in India, Serum Institute of India, has successfully completed an FDA inspection. Erck told analysts during the company’s first-quarter earnings call that he fully expects the committee will authorize the vaccine for adults.

Chief Commercial Officer John Trizzino, in an interview with Bank of America, said all signs point toward a positive recommendation from the committee next month.

“We’re fully expecting based upon our submission, based upon all the back and forth questions that have been asked and answered, based upon the inspection at Serum, to come out of that meeting with a recommendation for emergency use authorization,” Trizzino said during Bank of America’s virtual health-care conference on Wednesday evening.

The FDA has been reviewing Novavax’s submission for months. The vaccine maker asked the drug regulator to authorize the vaccine in January, but federal health officials said the application was complex.

“This is an incredibly complex review process that involves review of not just clinical data but also manufacturing data that will be needed to make a determination about emergency use authorization,” Dr. Doran Fink, deputy director of clinical review at the FDA’s vaccine division, told the Centers for Disease Control and Prevention’s committee of independent vaccine advisors last month.

If Novavax’s vaccine is authorized by the FDA, it will be first new shot to hit the market in the U.S. in more than a year. Pfizer, Moderna and Johnson & Johnson are the three vaccines currently used in the U.S., and the FDA last week limited the use of J&J’s shots.

The vaccine would enter the U.S. market at a time when 76% of adults are already fully vaccinated. Trizzino said on Wednesday that Novavax’s shots would offer choice to the remainder of the adult population that would prefer not to receive an mRNA vaccine. Novavax’s vaccine uses more conventional protein technology, whereas Pfizer’s and Moderna’s use messenger RNA platforms first authorized during the coronavirus pandemic. Trizzino said the shots could also play an important role as booster doses and in teenagers ages 12 to 17.

Novavax has submitted its data from teenagers to the FDA and is also filing data on booster doses, Chief Medical Officer Philip Dubovsky said during the company’s earnings call. It’s unclear, however, when the FDA may consider the company’s shots for teens and as booster doses.

FDA authorization of the vaccine would come right as the drug regulator is considering redesigning Covid shots this fall to target mutations the virus has developed over the past two years. All of the current vaccines, including Novavax, target the spike protein of the original strain of the virus that emerged in Wuhan, China, in 2019. As the virus has evolved, the shots have become less effective at blocking infections.

Novavax plans to launch a clinical trial this month on a version of the vaccine that targets omicron mutations, Erck said during the company’s earnings call. Trizzino, during the Bank of America interview, said the goal is to have the shots ready by October for a fall vaccination campaign should the FDA decide to move forward with updating the shots.

“Our thinking is in the fall, we need to be ready to do what our customer wants,” Trizzino said, referring to the U.S. government. “We intend to have the clinical data, the package that’s filed for that and then be able to deploy in the timeframe of October.”

It’s unclear how many shots the U.S. government would order should the vaccine receive authorization. Erck said Novavax is in discussions now with the U.S. on how the company can support demand. Novavax has received $1.8 billion from the U.S. government under Operation Warp Speed to deliver 100 million doses, though the government will decide how many shots it wants after FDA authorization.

Novavax stock has dropped 13% this week due to uncertain demand for the shots and after the company missed Wall Street’s first-quarter earnings and revenue expectations. Although Novavax maintained its 2022 sales guidance of $4 billion to $5 billion, CFO Jim Kelly said the company has not yet received an order from COVAX, the international alliance that procures shots for poorer nations. It’s unclear how much COVAX may order, Kelly said, which could put downward pressure on the sales guidance.

Last year, Novavax signed a memorandum of understanding to make 1.1 billion doses of its vaccine available to COVAX, and the company previously said it has the capacity to manufacture 2 billion doses in 2022. However, Novavax’s vaccine rollout around the world has gotten off to a sluggish start this year.

Novavax delivered 42 million doses in the first quarter to markets where the vaccine is already authorized, including the European Union, Canada, South Korea, Australia, New Zealand and Indonesia. However, the company expects shipments and revenue to increase in the second quarter as its fulfills an order of 42 million doses from the EU, Trizzino told analysts during the earnings call.

Novavax’s vaccine uses different technology than Pfizer’s and Moderna’s shots. The Pfizer and Moderna vaccines deliver mRNA to the body’s cells, which then produce harmless copies of the virus spike protein, which induces an immune response that fights Covid. The spike protein is the tool the virus uses to invade human cells.

Novavax’s fully synthesizes the copies of the spike protein outside the human body. The company inserts the genetic code for spike in a baculovirus which then infects cells for a certain type of moth. Novavax then harvests the spike from those cells and purifies them for the shot. The vaccine also uses what’s known as adjuvant, purified from the bark of a South American tree, to boost the immune response.

Novavax’s U.S. and Mexico clinical trial found that its vaccine was 90% effective at preventing mild illness and 100% effective at preventing severe illness. However, the trial was conducted well before the omicron variant emerged, which has undermined vaccine effectiveness against infection.

Novavax released results from a lab study in December which found that its vaccine still triggered an immune response against omicron. The study found that a third boosted the immune response to levels similar to the U.S. and Mexico clinical trial, suggesting a high level of protection with a third shot.



SpaceX president defends Elon Musk over sexual misconduct allegations




SpaceX CEO Elon Musk participates in a postlaunch news conference inside the Press Site auditorium at NASA’s Kennedy Space Center in Florida on May 30, 2020, following the launch of the agency’s SpaceX Demo-2 mission to the International Space Station.

NASA/Kim Shiflett

SpaceX President and COO Gwynne Shotwell defended Elon Musk in an email to employees last week, responding to sexual misconduct allegations directed at the CEO, CNBC has learned.

“Personally, I believe the allegations to be false; not because I work for Elon, but because I have worked closely with him for 20 years and never seen nor heard anything resembling these allegations,” Shotwell wrote in a companywide email sent on Friday and seen by CNBC.

Musk has denied the allegations, which claim he propositioned a flight attendant on one of SpaceX’s private jets in 2016, calling them “wild accusations.”

In a response to Business Insider, which reported the allegations and that the flight attendant was paid $250,000 severance after confronting the company, Musk said there is “a lot more to this story,” describing it as a “politically motivated hit piece.” Neither Musk nor SpaceX’s vice president of the legal department, Christopher Cardaci, denied the payment in statements to Business Insider.

Shotwell emphasized in her email that she “will never comment on any legal matters involving employment issues” before noting Musk publicly denied the allegations as “utterly untrue” in a tweet.

Shotwell, who is No. 2 at SpaceX and the company’s top female executive, also noted in the email that SpaceX has a “ZERO tolerance” policy for harassment, adding that every accusation is taken seriously and investigated, “regardless of who is involved.”

SpaceX did not immediately respond to CNBC’s request for comment on Shotwell’s email.

SpaceX President and COO Gwynne Shotwell

Jay Westcott / NASA


Continue Reading


Judge blocks auction of ‘Wizard of Oz’ dress by Catholic University




A blue and white checked gingham dress, worn by Judy Garland in the “Wizard of Oz,” hangs on display, Monday, April 25, 2022, at Bonhams in New York.

Katie Vasquez | AP

A federal judge in New York blocked Tuesday’s scheduled auction of a dress worn by Judy Garland in “The Wizard of Oz” that had been expected to fetch up to $1 million or more for The Catholic University of America.

Monday’s injunction barring a sale of the dress by Bonhams auction house in Los Angeles came more than two weeks after a Wisconsin woman sued to stop the sale, claiming it belonged to the estate of her late uncle, the Rev. Gilbert Hartke.

Barbara Hartke’s lawsuit now will proceed in Manhattan federal court.

Judge Paul Gardephe ordered Catholic U., which is located in Washington, D.C., and Bonhams not to sell the dress until the lawsuit is resolved.

Anthony Scordo, the attorney for Barbara Hartke, in an email to CNBC said, “I am pleased with the ruling preventing the sale.”

” I feel the judge carefully reviewed the submissions of all parties and came to a fair result,” Scordo said.

CNBC Politics

Read more of CNBC’s politics coverage:

Hartke received the “Oz” dress in 1973 as a gift from Academy Award-winning actress Mercedes McCambridge while serving as head of Catholic U.’s drama school, which he founded. It is not known how MacCambridge obtained the costume from the classic 1939 film.

As an heir to the priest, Barbara Hartke stands to inherit a fraction of the ownership dress if she prevails in her lawsuit.

The dress had been missing for decades before it was found in a trash bag in a room at the drama school last year. Catholic U. then moved to put it up for auction, generating widespread media coverage last month.

Catholic U. argues that it is the legal owner of the dress, because Hartke, as a Roman Catholic priest, had taken a vow of poverty and that the dress was intended to benefit the school.

The school also submitted affidavits from a grand-nephew of Hartke who remembered that “my grand-uncle Father Gilbert Hartke said to me that I could not have it as the dress belonged to Catholic University.”

That man, Thomas Kuipers, with a cousin said that they and other descendants of the priest supported the auction of the dress with the understanding that it was given as a gift for the school.

The dress is one of only two dresses known to still exist of the several created for Garland to wear in “The Wizard of Oz.”

The other dress was auctioned in 2015 by Bonhams for more than $1.5 million.   


Continue Reading


As number of billionaires climbs, new calls for wealth taxes emerge




A mobile billboard calling for higher taxes on the ultra-wealthy depicts an image of billionaire businessman Jeff Bezos, near the U.S. Capitol on May 17, 2021 in Washington, DC.

Drew Angerer | Getty Images

A new billionaire was created on average about every 30 hours during the Covid-19 pandemic, according to a new report by Oxfam, a global charity focused on eliminating poverty.

Now, 573 more people around the world can claim billionaire status compared to 2020 when the pandemic began, for a current total of 2,668 billionaires.

At the same time, their wealth has soared 42% or $3.78 trillion during the Covid-19 pandemic, for a current total of $12.7 trillion.

Yet 263 million people are at risk of falling into extreme poverty this year, signaling deepening wealth inequality exacerbated by the pandemic.

More from Personal Finance:
High net worth philanthropy not driven just by tax breaks
A ‘bear market’ looms. What exactly does that mean?
Climbing interest rates mean good news for annuity buyers

The widening divide between the haves and have-nots highlights the need for more taxes on the wealthiest, according to Oxfam.

“We really need for Congress to step in and for the administration to step in and tax the most wealthy in our society so that we can really start to invest in public services and in working people,” said Irit Tamir, director of the private sector department at Oxfam America.

The report comes as business leaders, politicians and billionaires meet face-to-face this week in Davos, Switzerland, for the first time in two years.

Political leaders on Capitol Hill, including President Joe Biden, have put forward their own proposals to make the wealthy pay more.

“Right now, the average billionaire — there are about 790 of them or so in America — has a federal tax rate of 8%,” Biden tweeted on Sunday.

“No billionaire should be paying a lower tax rate than a teacher, a firefighter, an electrician or a police officer,” he said.

There are two main ways policy makers can “tax the rich,” according to Howard Gleckman, senior fellow at the Urban-Brookings Tax Policy Center.

That includes either taxing the income or taxing the wealth of rich people.

“Generally, what we do in the U.S. is we tax income,” Gleckman said. “We don’t really tax wealth.”

That could change, based on some proposals that have been put forward. One key idea that has received attention is taxing unrealized capital gains, or the value of assets that have not yet been sold.

This may be tricky with privately held businesses, particularly when it comes to determining a value both the IRS and owners can agree on. Consequently, one idea from Sen. Ron Wyden, D-Ore., calls for applying this tax annually to just publicly-traded assets. Other non-traded assets would instead be taxed when they are sold.

This approach could become complicated for taxpayers if the value of their assets declines, and they have to reconcile the taxes they have already paid.

Another approach would be to get rid of a mechanism that allows people to avoid paying taxes on the increases in the value of assets over their lifetimes, formally known as a step-up in basis at death.

For example, suppose you buy a stock for $10, and then it is worth $100 when you die. When your heirs receive the stock, their basis will be $100, based on current rules. Consequently, they will not be taxed on the $90 increase in value that happened during your lifetime.

That could be changed so that heirs will owe taxes on any gains since the original cost basis, or the $10 at which you originally purchased the stock.

However, one key disadvantage to this change is it would take a long time for the government to raise revenue, since it requires the stock owner to die and for their heir to sell it. “That can take decades,” Gleckman said.

With any of the proposals, the government will have to strike a balance between generating money and trying to limit the administrative challenges any implemented changes require.

Most Americans will never have to worry about paying these taxes, even if they have $5 million or $10 million in assets.

“This is really for people with extreme wealth,” Gleckman said.


Continue Reading